Infliximab effect on serum IGF-1 and IGFBP-3 in active inflammatory bowel disease

Το τεκμήριο παρέχεται από τον φορέα :

Αποθετήριο :
Annals of Gastroenterology
δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
κοινοποιήστε το τεκμήριο

Infliximab effect on serum IGF-1 and IGFBP-3 in active inflammatory bowel disease (EN)

Katsanos1, A. Tsatsoulis2, V. Cholevas3, Anna Challa3, E.V. Tsianos1, K.H.

AIM: There are few studies that have investigated the changes of the insulin-like growth factor (IGF) system in inflammatory bowel disease (IBD) and the majority of these studies have examined the alterations of the GH-IGF axis in growth-retarded IBD children. Moreover, the impact of the chimeric monoclonal anti-TNFá antibody (Infliximab) in the IGF system in patients with Crohn’s disease (CD) or ulcerative colitis (UC) has not yet been investigated. PATIENTS-METHOD: Five IBD patients (3 with Crohn’s and 2 with ulcerative colitis) and five age and sex matched controls were included in this study. In all patients and controls a baseline serum sample for IFG-1, IGFBP-3 and IL-6 was obtained one week before Infliximab treatment initiation. During the first four times of Infliximab administration morning fasting serum samples were obtained from each patient. At the same time, fasting morning control samples were also obtained. RESULTS: Short-term effect of infliximab administration (baseline-1st dose comparison) resulted in a statistically significant increase in serum IGFBP-3 levels (p=0.39) while no statistically significant change was noticed in IL-6 and IGF-1 levels. After four doses of Infliximab (long term effect, baseline-4th dose comparison) a statistically significant increase in serum IGF-1 and IGFBP-3 levels was noticed (p=0.02 in both parameters) while IL-6 was decreased to a statistically significant exlent (p=0.01). DISCUSSION: This study demonstrated that Infliximab can influence the IGF system in IBD patients. This increase of serum IGF-1 and IGFBP-3 with concomitant decrease in IL-6, may represent a probable mechanism through which this drug acts in these patients, in whom there is a evidence of an impaired GH/IGF axis. Key words: inflammatory bowel disease, ulcerative colitis, Crohn’s disease, infliximab, IGF system, interleukin (EN)


Αγγλική γλώσσα


Hellenic Society of Gastroenterology (EN)

Annals of Gastroenterology; Volume 18, No 1 (2005) (EN)

*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.